Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hMPV_Y low dose vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
hMPV_Y low dose vaccine is an investigational human metapneumovirus (hMPV) vaccine candidate developed by GSK. It was evaluated as part of a Phase 1/2 clinical trial (NCT04141540) designed to assess the safety, reactogenicity, and immunogenicity of various hMPV and RSV/hMPV combination vaccine formulations in younger adults (18-49 years) and older adults (60-80 years). The 'Y' designation refers to a specific investigational formulation of the hMPV vaccine, administered at a low dose via intramuscular injection. The vaccine aims to elicit a protective immune response against hMPV, a significant cause of viral respiratory tract infections, particularly in infants, the elderly, and immunocompromised individuals.
02
Targets
HMPV F (Human metapneumovirus fusion protein)TCR (T-cell receptor (TCR) recognizing human metapneumovirus (hMPV) fusion (F) protein-derived peptides presented by major histocompatibility complex (MHC))
Beyond the preview
Go deeper on hMPV_Y low dose vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hMPV_Y low dose vaccine.